DO-BO

How Can Europe Move from Innovation Paradox to Powerhouse,  Cuno Moser?

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer engages with Swiss healthcare strategist Cuno Moser to explore Europe’s “innovation paradox” in healthcare. Despite its strengths in research, data quality, and clinical expertise, Europe struggles to transform pilot projects into scalable, reimbursable solutions. With over 27 fragmented reimbursement systems in the EU and in Switzerland, significant barriers impede progress in digital health, medtech, and AI-driven care. Beyond funding, challenges such as misaligned incentives, insufficient execution infrastructure, and flawed system design keep innovation stuck in “pilot purgatory.”

Looking ahead, while Europe may not lead in speed, it has the opportunity to excel in quality and trust. This could allow European health platforms to establish a competitive edge. If you’re involved in digital health, medtech, AI, or market access and find your solution stalled between a promising pilot and real-world scalability, this episode is a must-listen.

https://www.linkedin.com/feed/update/urn:li:activity:7437804838232453120/

Related

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]

From Olympic ice to AI-powered leadership: What can Market Access teams learn from elite sports? In the 111+1 anniversary episode of MAP – the Market Access Podcast, Dr. Stefan Walzer interviews Livia Altmann, a former Swiss Olympic ice hockey player who has transitioned into a leadership and “Human Intelligence 2.0” expert. Together, they explore how […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer speaks with Sreeram Ramagopalan, a global expert at the intersection of biotech value, HTA, real‑world evidence and market access. Together they unpack how the UK NICE threshold increase (from £20–30k to £25–35k per QALY) and US reforms (IRA, MFN) are quietly […]